Results 41 to 50 of about 12,743 (165)
Objective. To systematize available information regarding mutations that confer resistance to first-line anti-tuberculosis drugs. Materials and Methods.
Aiko Vigo +3 more
doaj +1 more source
Role of rpsA Gene Sequencing in Diagnosis of Pyrazinamide Resistance [PDF]
We read with great interest the article by Alexander and colleagues ([1][1]) on the frequency of rpsA mutations in pyrazinamide-susceptible and resistant isolates with a wild-type pncA gene. In contrast to the report of Shi and colleagues ([2][2]), Alexander and colleagues could not find any ...
Simons, SO +4 more
openaire +5 more sources
Background: The first line anti-tuberculosis drug pyrazinamide (PZA) is important when treating PZA susceptible multidrug-resistant tuberculosis (MDR-TB). Several drug resistance surveys have however reported PZA resistance among a significant proportion
Mikael Mansjo +2 more
doaj +1 more source
Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host‐Directed Strategies
ABSTRACT The global burden of multidrug‐resistant tuberculosis (MDR‐TB) and the rising incidence of nontuberculous mycobacterial (NTM) infections highlight the urgent need for innovative therapeutic strategies. Current treatments are prolonged, toxic, and increasingly compromised by resistance and limited diagnostic capacity.
Tânia Silva +23 more
wiley +1 more source
Pyrazinamide (PZA), a crucial component of anti-TB therapy, is a prodrug. PZA interacts with PncA protein to be converted into its functional form i.e. pyrazinoic acid (POA). It has unique feature to kill dormant tubercle bacilli of acidic environment.
Gaurava Srivastava +2 more
openaire +2 more sources
The Patterns of Conversion to Anti-Tuberculosis Drug Resistance in Mycobacterium tuberculosis
The prevalence of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are increasing. We analyzed the patterns of drug resistance and tracking period days of acquiring anti-mycobacterial resistance.
Moo-Sang Chong, Kyutaeg Lee
doaj +1 more source
Altered Pharmacokinetics and Delayed Sputum Conversion in Tuberculosis Patients Co‐Infected With HIV
ABSTRACT Background HIV co‐infection affects host responses and pharmacokinetics (PK) of tuberculosis (TB) treatment. This study assessed the PK of first‐line anti‐TB drugs and clinical outcomes in patients with and without HIV co‐infection. Methods In this prospective observational study, 61 adults with sputum‐positive pulmonary TB, either confirmed ...
Aung Pyae Phyo +14 more
wiley +1 more source
Abstract The availability of safety data, particularly concerning adverse events (AEs) associated with the new shorter regimen for drug‐resistant tuberculosis (TB) containing a bedaquiline–pretomanid‐based regimen, is still limited. This systematic review aims to provide a comprehensive and updated analysis of AEs related to this new regimen by ...
Nisa Maria +4 more
wiley +1 more source
Introduction: In Kenya, which ranks thirteenth of 27 high tuberculosis burden countries, diagnosis is based on Ziehl-Neelsen staining alone and patients are treated without information on sensitivity patterns.
Perpetual Wangui Ndung'u +3 more
doaj +1 more source
Pretomanid is a component of the World Health Organization‐recommended treatment regimen for drug‐resistant tuberculosis in patients aged ≥ 14 years. While preclinical rodent studies identified testicular toxicity as a potential clinical liability at elevated doses, no corresponding effects were observed in nonhuman primates nor clinical hormone ...
Pauline Howell +13 more
wiley +1 more source

